Adinazolamum Uses, Dosage, Side Effects and more
Adinazolamum (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolamum was first developed to enhance the antidepressant effects of alprazolam. It has never been approved by the FDA for clinical use.
Adinazolamum is a benzodiazepine derivative used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia. Adinazolamum binds with high affinity to the GABA benzodiazepine receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of alprazolam are mediated via interaction with this receptor complex.
| Attribute | Details |
|---|---|
| Trade Name | Adinazolamum |
| Generic | Adinazolam |
| Adinazolam Other Names | Adinazolam, Adinazolamum |
| Type | |
| Formula | C19H18ClN5 |
| Weight | Average: 351.833 Monoisotopic: 351.125073308 |
| Groups | Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
For the treatment of anxiety and status epilepticus.
How Adinazolamum works
Adinazolamum binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
Toxicity
Signs of overdose may include muscle weakness, ataxia, dysarthria and particularly in children paradoxical excitement. In more severe cases diminished reflexes, confusion, and coma may ensue.
Half Life
Less than 3 hours.
